Systemic Consequences and Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Action!

KU Leuven200 enrolled

Overview

The aim of this prospective case-control study is to investigate the prevalence, severity and incidence of systemic consequences in newly detected patients with mild and moderate Chronic obstructive pulmonary disease (COPD). Special attention will be paid to skeletal muscle dysfunction and physical inactivity as these factors are, together with smoking, potentially modifiable.

Three groups will be included in this study: * Patients with COPD (cases) * Patients with smoking history but no COPD (smoking controls) * Patients with no smoking history and no COPD (non-smoking controls) An extensive test battery will be performed at baseline and after 3 years: Clinical assessment (height, weight and blood pressure)\* Complete pulmonary function ((post-bronchodilator)spirometry + diffusion)\* Sputum Induction Fasting venous blood sample (fasting glucose, cholesterol, triglycerides, inflammatory markers, creatinine, NT pro BNP, hemoglobin, testosterone, vitamin D) Vascular screening (arterial stiffness - arterial stenosis - CIMT) Muscle force (peripheral + respiratory)\* Functional exercise capacity (6 MWT)\*\* Maximal exercise capacity (incremental cycle test)\*\* Dexa scan (osteoporosis - body composition) Spiral CT scan of the chest RX thorax - RX lumbar Questionnaires (MRC, CCQ, SF-36, EQ5D, HADS, Exacerbation, CATZ)\*\* Physical activity monitoring (sensewear armband)\* \* test will be repeated every 6 months \*\* test will be repeated every year !!!! Remark (26/9/2013) Based on the last data analyses, in contrast to our expectations, we concluded that the two groups with a smoking history, with or without COPD change in a similar way over time. The length of the study will therefore be prolonged with 3 more years (6 years in total). After 3 years the patients with a smoking history will be evaluated yearly, unless they were hospitalized for \>5 days. In that case we will sooner contact these patients in order to pick up comorbidities in these patients.!!!

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Chronic Obstructive Pulmonary Disease

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * age 40-80 years old cases: spirometry (post-bronchodilator) based diagnosis of COPD (GOLD criteria) + smoking history of at least 10 pack-years and active smoking behavior till at least 10 years from the moment of enrollment. smoking controls: no COPD (spirometry based) + smoking history of at least 10 pack-years and active smoking behavior till at least 10 years from the moment of enrollment. non-smoking controls: no COPD (spirometry based) + \< 1 pack year Exclusion Criteria: * Respiratory disorder other than COPD * α1-antitrypsin deficiency * Known history of significant inflammatory disease other than COPD * COPD exacerbation within 4 weeks prior to study * Lung surgery * Recent diagnosis of cancer * Therapy with oral corticosteroids in the last 6 weeks * Significant cardiovascular comorbidity * Significant orthopedic/musculoskeletal problems

Locations (1)

University Hospital Leuven

Leuven, Belgium

Outcomes

Primary Outcomes

Prevalence of risk factors to develop comorbidities (vascular dysfunction, osteoporosis, muscle wasting and metabolic syndrome)

Common risk factors: smoking, COPD, physical inactivity (steps (per day)and moderate intense PA (min/day) and systemic inflammation (CRP, fibrinogen, IL-6, IL-8, TNF-alpha). Specific risk factors: vascular (atherosclerosis (mean IMT carotid arteries), arterial stenosis (ankle brachial index) and arterial stiffness (brachial ankle pulse wave velocity)), bone (osteopenia: T-score \< -1 at lumbar spine/femoral neck/total femur), muscle (fat free mass index \< 15/16(female/male) and respiratory/peripheral muscle weakness; \< 80%predicted), metabolic (syndrome): definition by AHA

Time frame: baseline

Incidence and worsening of risk factors to develop comorbidities (vascular dysfunction, osteoporosis, muscle wasting and metabolic syndrome)

Common risk factors: smoking, COPD, physical inactivity (steps (per day)and moderate intense PA (min/day) and systemic inflammation (CRP, fibrinogen, IL-6, IL-8, TNF-alpha). Specific risk factors: vascular (atherosclerosis (mean IMT carotid arteries), arterial stenosis (ankle brachial index) and arterial stiffness (brachial ankle pulse wave velocity)), bone (osteopenia: T-score \< -1 at lumbar spine/femoral neck/total femur), muscle (fat free mass index \< 15/16 (female/male) and respiratory/peripheral muscle weakness; \< 80%predicted), metabolic (syndrome): definition by AHA

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.